Halozyme Therapeutics (HALO) Tops Q4 EPS by 2c, FY Guidance Beats
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $103.00 --0%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
HSAI, SYRS, EGRX, More
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
HSAI, SYRS, EGRX, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $60.2 million versus the consensus estimate of $59.77 million.
GUIDANCE:
Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of $168.8 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- VNET Group (VNET) Misses Q2 EPS by 164c
- Prenetics IM8 revenue jumps 359% in Q2, raises FY2026 guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
